NovoSeven is a blockbuster, but continued growth at a high rate is problematic due to the colossal cost per dose. Lowering production cost is the impetus for GTC’s rFVIIa program with LFB.
Source of graphic: Novo Nordisk
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.